← Product Code [LAF](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/LAF) · K080455 # RAPIDSENSE DRUGS OF ABUSE METHAMPHETAMINE (MET) 1000 DEVICE, MODEL 900-0050 (K080455) _Quantrx Biomedical Corporation · LAF · Dec 31, 2008 · Clinical Toxicology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/LAF/K080455 ## Device Facts - **Applicant:** Quantrx Biomedical Corporation - **Product Code:** [LAF](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/LAF.md) - **Decision Date:** Dec 31, 2008 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.3610 - **Device Class:** Class 2 - **Review Panel:** Clinical Toxicology ## Indications for Use The RapidSense™ Drugs of Abuse Methamphetamine (MFT) 1000 Device is a lateral flow competitive immunoassay intended for the qualitative detection of Methamphetamine in human urine at a cut-off concentration of 1000 ng/mL. The assay is intended for use in professional laboratories by healthcare professionals. For in vitro diagnostic use. This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas chromatography/mass spectroscopy (GC/MS) is the recommended confirmatory method. Tests for methamphetamine cannot distinguish between abused drugs and certain prescribed medications. Certain foods or medications may interfere with tests for methamphetamine and cause false positive results. ## Device Story Single-use lateral flow cassette; detects methamphetamine in human urine. Operator adds urine sample to well; sample migrates through strip via capillary action. Principle: competitive immunoassay using monoclonal mouse anti-methamphetamine antibody and blue latex-labeled antigen conjugates. Differential migration mechanism: analyte at/above cutoff prevents antibody binding in primary capture zone, allowing latex-conjugate to migrate to secondary capture zone, forming visible test line (positive result). Absence of analyte allows binding in primary zone, preventing test line formation (negative result). Internal process control confirms sample volume and strip integrity. Used in professional laboratories; results interpreted visually by healthcare professionals. Preliminary result requires GC/MS confirmation for clinical decision-making. ## Clinical Evidence Method comparison study evaluated 84 clinical urine samples (40 negative, 44 positive) against GC/MS reference method. Results showed 75% agreement among positives and 100% agreement among negatives. Precision study (n=20 per concentration) across 10 days confirmed performance around the 1000 ng/mL cutoff. Analytical specificity and interference testing (pH, specific gravity, common compounds) showed no significant interference. ## Technological Characteristics Lateral flow immunochromatographic assay; cassette format. Reagents: monoclonal mouse anti-methamphetamine antibody, mouse monoclonal anti-protein A antibody, blue latex-labeled antigen conjugates. Qualitative, visually read. No instrumentation required. Standard: CEN 13640 (stability). ## Regulatory Identification A methamphetamine test system is a device intended to measure methamphetamine, a central nervous system stimulating drug, in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of methamphetamine use or overdose. ## Special Controls *Classification.* Class II (special controls). A methamphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military). ## Predicate Devices - ACON mAMP One Step Methamphetamine Test Strip and Test Device (k011672) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE ONLY TEMPLATE A. 510(k) Number: k080455 B. Purpose for Submission: New device C. Measurand: Methamphetamine D. Type of Test: Qualitative immunoassay E. Applicant: QuantRx Biomedical Corporation F. Proprietary and Established Names: RapidSense Drugs of Abuse Methamphetamine (MET) 1000 Device G. Regulatory Information: 1. Regulation section: 21 CFR 862.3610, Thin Layer Chromatography, Methamphetamine 2. Classification: Class II 3. Product Code: DJC 4. Panel: Toxicology (91) {1} Page 2 of 8 ## H. Intended Use: 1. **Intended use(s):** Refer to indications for use below. 2. **Indication(s) for use:** The RapidSense Drugs of Abuse Methamphetamine (MET) 1000 Device is a lateral flow competitive immunoassay for the qualitative detection of methamphetamine in human urine at a cutoff concentration of 1000 ng/mL. The assay is intended for use in professional laboratories by healthcare professionals. For in vitro diagnostic use. This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternative chemical method is needed. Gas chromatography/Mass spectroscopy (GC/MS) is the recommended confirmatory method. 3. **Special condition for use statement(s):** This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternative chemical method is needed. Gas chromatography/Mass spectroscopy (GC/MS) is the recommended confirmatory method. The assay is not designated for use in point-of-care settings. The assay is for prescription use only. 4. **Special instrument Requirements:** Not applicable. The device is a visually read single-use device. ## I. Device Description: The product is a single-use device in a cassette format. Operators add several drops of the sample to the sample well. The test reaction is initiated by movement of the sample through the test strip. {2} Page 3 of 8 Description of the test antibody: monoclonal mouse antibody against methamphetamine. Description of the control line antibody: mouse monoclonal antibody against protein A (Protein A binds with the colloidal gold) ## J. Substantial Equivalence Information: 1. Predicate device name(s): ACON mAMP One Step Methamphetamine Test Strip and Test Device 2. Predicate K number(s): k011672 3. Comparison with predicate: Both devices are for the qualitative determination of the same analyte in the same matrix, and utilize the same cutoff concentration. Both are visually-read single use devices. The devices differ in interpretation of the test line. The presence of the test line indicates a negative result for the predicate and a positive result for the new device. ## K. Standard/Guidance Document Referenced (if applicable): The sponsor referenced the following guidance document(s) in their submission: CEN 13640, Stability Testing of In Vitro Diagnostic Reagents ## L. Test Principle: The test employs lateral flow immunochromatographic technology. The QuantRx assay is a positive read type test with a differential migration mechanism. The free analyte runs ahead of and continuous with the blue colored latex labeled antigen conjugates and reacts with the antibody immobilized in the primary capture zone. The primary capture zone is located under the top of the cassette, not visible to the user. When analyte is at or above the cutoff concentration, less antibody in the primary capture zone is available to bind with the latex-analyte conjugate. Thus more latex-analyte conjugate migrates beyond the primary capture zone to the secondary capture zone where it forms a test line visible to the reader. When the drug analyte is absent or below the cut off, the latex-conjugate binds with {3} Page 4 of 8 the antibody in the primary capture zone and no line forms at the secondary capture zone (T) resulting in a negative result (no test line). The internal process control indicates that an adequate volume of sample has been added and that the immunochromatographic strip is intact. ## M. Performance Characteristics (if/when applicable): ### 1. Analytical performance: #### a. Precision/Reproducibility: Specimen description: commercially available drugs of abuse controls containing methamphetamine Number of days: ten Replicates per day: two Lots of product used: two Number of operators: two Operator: manufacturer staff Testing Facility: manufacturer Results of the study are presented below: Methamphetamine Precision Study Results | Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos | | --- | --- | --- | | 0 | 20 | 20/0 | | 500 | 20 | 20/0 | | 750 | 20 | 15/5 | | 1000 | 20 | 4/16 | | 1250 | 20 | 4/16 | | 1500 | 20 | 0/20 | #### b. Linearity/assay reportable range: Not applicable. The assay is intended for qualitative use. #### c. Traceability (controls, calibrators, or method): Control materials are required but are not specifically identified in the labeling. {4} The device has an internal process control. Users are instructed to follow government regulations when determining when to run external controls. # d. Detection limit: Sensitivity of this assay is characterized by validating performance around the claimed cutoff concentration of the assay, including a determination of the lowest concentration of drug that is capable of producing a positive result. This information appears in the precision section, 1.a. above. # e. Analytical specificity: Cross-reactivity was established by spiking various concentrations of similarly structured drug compounds into drug-free urine. By analyzing various concentration of each compound the sponsor determined the concentration of the drug that produced a response approximately equivalent to the cutoff concentration of the assay. Results of those studies appear in the table below: Methamphetamine | Drug Compound | Response equivalent to cutoff in ng/mL | | --- | --- | | d-amphetamine | >50,000 | | Chloroquine | >100,000 | | l-methamphetamine | 2,500 | | 3,4-Methylenedioxyethylamphetamine (MDEA) | 20,000 | | D,L 3,4-Methylenedioxymethamphetamine (MDMA) | 500 | | Procaine | >10,000 | | B-Phenylethylamine | >50,000 | | Ranitidine | 50,000 | | Ephedrine | 50,000 | The following compounds were evaluated for potential positive and/or negative interference with the assay. To evaluate for interference the sponsor prepared two control samples that consisted of drug-free urine spiked with 500 and $1500\mathrm{ng / mL}$ of methamphetamine. $100~\mu \mathrm{g / mL}$ of potentially interfering compounds were then added to separate aliquots of the control samples and analyzed. No positive or negative interference was observed. The compounds tested were: {5} Page 6 of 8 | Acetaminophen | Chlorpheniramine | Hemoglobin | | --- | --- | --- | | Acetone | Creatine | Imipramine | | Albumin | Dextromethorphan | Isoproterenol | | Amitryptyline | 4-dimethylaminoantipyrine | Lidocaine | | Aspartame | Erythromycin | Penicillin G | | Aspirin | Ethanol | Pheniramine | | Atropine | Furosemide | Quinidine | | Benzocaine | Glucose | Sulindac | | Caffeine | Guaiacol Glycerol Ether | Vitamin C | There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false. To test for possible positive and/or negative interference from specific gravity, the sponsor prepared two study control samples. The control samples consisted of drug-free urine spiked with 500 and 1500 ng/mL of methamphetamine. Aliquots of the control samples were then altered to span the specific gravity range of 1.007 to 1.031. No positive or negative interference due to specific gravity was observed. To test for potential negative interference from pH the sponsor prepared a study control sample consisting of drug-free urine spiked with 1500 ng/mL of methamphetamine. Aliquots of the control samples were then adjusted to a pH range of 3 - 9 and analyzed. No negative interference due to pH was observed. f. Assay cut-off: Characterization of how the device performs analytically around the claimed cutoff concentration appears in the precision section, 1.a, above. 2. Comparison studies: a. Method comparison with predicate device: A total of 84 samples (40 negative and 44 positive) were evaluated by the candidate device and by GC/MS. Sample description: Unaltered clinical urine samples were evaluated. Sample selection: Samples were selected based on previous GC/MS values. {6} Page 7 of 8 The study included an adequate number of samples that contained drugs near to the cutoff concentration of the assay. Approximately 10% of the study samples are evenly distributed between plus and minus 50% of the claimed cutoff concentration. Number of study sites: one Type of study site: clinical setting Operator description: clinical site staff ## Candidate Device Results vs. stratified GC/MS Values | Candidate Device Results | Less than half the cutoff concentration by GC/MS analysis | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) | | --- | --- | --- | --- | --- | | Positive | 0 | 0 | 12 | 21 | | Negative | 32 | 8 | 9 | 2* | GC/MS values used to categorize samples in this table are based on the concentration of methamphetamine found in the sample. % Agreement among positives is 75% % Agreement among negatives is 100% * The GC-MS concentrations of these samples were 2016 and 1620. b. Matrix comparison: Not applicable. The assay is intended for only one sample matrix. 3. Clinical studies: a. Clinical sensitivity: Not applicable. Clinical studies are not typically submitted for this device type. b. Clinical specificity: {7} Page 8 of 8 Not applicable. Clinical studies are not typically submitted for this device type. c. Other clinical supportive data (when a and b are not applicable): 4. Clinical cut-off: Not applicable. 5. Expected values/Reference range: Not applicable. N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10 O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. --- **Source:** [https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/LAF/K080455](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/LAF/K080455) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com